Skip to main content

Table 2 Changes of clinical parameters at 3, 6 and 12 months after anti-VEGF treatment in BRVO eyes

From: Wide-field swept-source OCT angiography of the periarterial capillary-free zone before and after anti-VEGF therapy for branch retinal vein occlusion

Parameters BL 3 m 6 m 12 m P
RM one-way ANOVA Bonferroni post hoc test*
BL vs. 3 m BL vs. 6 m BL vs. 12 m
BCVA (ETDRS letters) 53.56 ± 16.09 63.37 ± 16.96 63.98 ± 13.48 65.67 ± 12.89 < 0.01 < 0.01 < 0.01 < 0.01
CRT (μm) 581.70 ± 191.90 283.70 ± 78.02 286.90 ± 85.19 262.50 ± 47.10 < 0.01 < 0.01 < 0.01 < 0.01
First-order artery
 PaCFZ area (mm2) 0.54 ± 0.18 0.47 ± 0.16 0.44 ± 0.16 0.41 ± 0.16 < 0.01 < 0.01 < 0.01 < 0.01
 Artery area (mm2) 0.49 ± 0.20 0.50 ± 0.20 0.50 ± 0.19 0.49 ± 0.20 0.05
 P/A ratio 1.14 ± 0.22 1.01 ± 0.21 0.94 ± 0.20 0.89 ± 0.17 < 0.01 < 0.01 < 0.01 < 0.01
Second-order artery
 PaCFZ area (mm2) 0.96 ± 0.48 0.83 ± 0.41 0.76 ± 0.40 0.73 ± 0.38 < 0.01 < 0.01 < 0.01 < 0.01
 Artery area (mm2) 0.60 ± 0.38 0.60 ± 0.37 0.60 ± 0.38 0.59 ± 0.37 0.20
 P/A ratio 1.83 ± 0.55 1.57 ± 0.53 1.45 ± 0.52 1.41 ± 0.49 < 0.01 < 0.01 < 0.01 < 0.01
  1. VEGF = vascular endothelial growth factor; BRVO = branch retinal vein occlusion; RM = repeated measures; ANOVA = analysis of variance; BL = baseline; BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; CRT = central retinal thickness; paCFZ = periarterial capillary-free zone; P/A = paCFZ area to artery area
  2. *Adjusted P value